13 results about "Heart Hypertrophy" patented technology

The application discloses application of a BLM helicase inhibitor in treating myocardial hypertrophy. The application firstly finds that the BLM helicase inhibitor ML216 can significantly inhibit cardiac hypertrophy and myocardial cell fibrosis, thereby providing a new drug for treating myocardial cell hypertrophy diseases in the field, and providing practical experimental evidence and scientific basis for treating myocardial cell hypertrophy diseases, and having a good application prospect in treating myocardial hypertrophy and / or cardiac hypertrophy.

A method for reducing pathological cardiac hypertrophy and / or inducing physiological cardiac hypertrophy by administering Nigella sativa or an extract thereof to a subject in need thereof, especially to an athletic subject in order to reduce exercise-induced pathological cardiac hypertrophy. A composition comprising Nigella sativa for use in said method.

The invention relates to the technical field of improvement of diabetic cardiomyopathy, and particularly discloses an application of a Spexin active polypeptide in preparation of a medicine for improving diabetic cardiomyopathy, the amino acid of the Spexin active polypeptide is NWTPQAMLYLKGAQ, and the medicine for improving diabetic cardiomyopathy is used for improving cardiomyopathy of mammals. The medicine for improving the diabetic cardiomyopathy further comprises pharmaceutically acceptable auxiliary materials and / or carriers, the Spexin active polypeptide is applied to preparation of the medicine for improving the diabetic cardiomyopathy, a new treatment thought and means are provided for the refractory disease, and animal experiments prove that the medicine has a good treatment effect on the diabetic cardiomyopathy. The Spexin active polypeptide can effectively reduce the blood sugar, the body weight and the length ratio of the heart to the tibia of a diabetic mouse, remarkably improve the cardiac function of the diabetic mouse and reduce the E / A peak, so that cardiac hypertrophy and cardiac dysfunction caused by diabetes are effectively relieved, and a remarkable treatment effect is shown.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.

A pharmaceutical composition containing an effective amount of cannabidiol (CBD) for use in treating or preventing a heart condition, along with related methods and uses. The heart conditions include heart failure, acute myocarditis, toxicity caused by anti-cancer therapies, acute pericarditis, cardiac sarcoidosis, inflammatory cardiomyopathy, and atherosclerosis and related uses and methods. The disclosure shows CBD to be effective in (i) reducing cardiac hypertrophy; (ii) reducing cardiac fibrosis; (iii) reducing the level of BNP; (iv) reducing the level of cytokine IL1β; (v) reducing the level of cytokine IL6; (vi) reducing the level of CD69; (vii) increasing the level of cytokine IL10, and (viii) combinations thereof. The composition is preferably adapted for parenteral administration.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for improving atrial fibrillation, a pharmaceutical preparation and a preparation method thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-26 parts of radix rehmanniae, 8-12 parts of honey-fried licorice root, 13-17 parts of sun-dried ginseng, 13-17 parts of poria cocos, 28-32 parts of dragon bone, 28-32 parts of nacre mother of pearl, 13-17 parts of schisandra chinensis, 22-26 parts of radix ophiopogonis, 10-14 parts of rhizoma corydalis, 18-22 parts of salvia miltiorrhiza, 7-12 parts of cassia twig and 13-17 parts of poria with hostwood. The traditional Chinese medicine composition is prepared from honey-fried licorice root, sun-dried ginseng, poria cocos, dragon bone, nacre mother of pearl, schisandra chinensis, radix ophiopogonis, rhizoma corydalis, salvia miltiorrhiza, cassia twig and poria with hostwood according to a specific proportion, can obviously improve the condition of heart function impairment, promote heart function recovery, protect the heart structure, improve cardiac hypertrophy, inhibit fibrosis and relieve atrial fibrillation symptoms, and is free of toxic and side effects, safe, reliable and free of toxic and side effects. Good application prospects are realized.

The invention discloses an application of a BLM helicase inhibitor in treatment of myocardial hypertrophy. It is found for the first time that the BLM helicase inhibitor ML216 can significantly inhibit cardiac hypertrophy and myocardial cell fibrosis, a new medicine is provided for treatment of the myocardial cell hypertrophy disease in the field, and meanwhile practical experimental evidence and scientific basis are provided for treatment of the myocardial cell hypertrophy disease. The compound has a good application prospect in the aspect of treating myocardial hypertrophy and / or cardiac hypertrophy.

A pharmaceutical composition comprising a diuretic and at least one additional active ingredient selected from the group consisting of ACE inhibitors, sartans, calcium channel blockers, alpha blockers, and beta blockers, wherein the diuretic is in a first pharmaceutical form that increases its dissolving rate. The invention also relates to the above composition for use in the treatment of a condition selected from heart failure, arterial hypertension, myocardial fibrosis, and cardiac hypertrophy.

The disclosure provides compositions comprising an inhibitory nucleic acid targeting IncExACTI, and methods of use thereof to improve cardiac function in a subject in need thereof. Specifically, the disclosure provides a cardiac long noncoding RNA (IncRNA), referred as IncExACT 1 (SEQ ID NO: 1), and inhibitory nucleic acids targeting IncExACT 1 for reducing expression of IncExACT 1 and / or Dachsous cadherin-related 2 (DCHS2) in a cell, e.g., a cell in a subject for improving cardiac function in a subject, wherein the subject has pathological cardiac hypertrophy and / or heart failure.

The invention provides application of a PPIA-BSG pathway inhibitor in preparation of a medicine for resisting myocardial hypertrophy after xenogenous heart transplantation, and belongs to the technical field of biological medicine. The PPIA-BSG axis is a key pathway for mediating myocardial hypertrophy after xenogenous heart transplantation. The PPIA inhibitor is utilized to target the pathway, so that the myocardial cell hypertrophy can be remarkably reduced, and a potential treatment strategy is provided for relieving malignant cardiac hypertrophy after xenotransplantation. In addition, extracellular PPIA can be inhibited by using a PPIA-BSG pathway related inhibitor, such as a non-immunosuppressor NIM811, and a remarkable curative effect is shown in the aspects of relieving myocardial hypertrophy and cell apoptosis. Therefore, the PPIA-BSG pathway inhibitor has the effect of resisting cardiac hypertrophy after xenogenic heart transplantation, and provides a treatment strategy and drug target information for cardiac hypertrophy after xenogenic heart transplantation.

The invention discloses an application of a water-soluble fullerene nano material in preparation of a medicine for treating and / or relieving heart failure. The treatment and / or relief of heart failure is embodied in at least one of the following aspects: 1) improving the systolic function of the heart; (2) the increase of the brain natriuretic peptide precursor content caused by heart failure is reduced; (3) the content of Ca < 2 + > in the failure heart is reduced; 4) improving cardiac hypertrophy caused by heart failure; 5) inhibiting cardiac fibrosis caused by heart failure; 6) reducing the active oxygen level of a heart pathologic region; 7) inhibiting inflammation of the heart failure part; and 8) inhibiting pyroptosis, apoptosis and cardiac fibrosis of the heart failure part. In a coronary artery ligation post-myocardial infarction heart failure mouse model, the FPs can regulate redox balance in a pathological area, reduce excessive inflammation, pyroptosis, apoptosis, cardiac hypertrophy and fibrosis of a heart failure part and improve a mouse cardiac systolic function, shows a good treatment effect, and is an ideal medicine for treating heart failure.

The application belongs to the field of FAM177A1 application research, and particularly relates to a new application of FAM177A1. Mainly disclosed are: application of a preparation for detecting FAM177A1 in preparation of a detection product for a myocardial cell hypertrophy disease; application of FAM177A1 or an expression promoter thereof in preparation of a medicine for treating the myocardial cell hypertrophy disease; application of FAM177A1 in preparation of a medicine for treating a disease induced by activation of a MAPK / ERK channel; and application of FAM177A1 in preparation of an inhibitor for non-diagnostic treatment activity of a MAPK enzyme. In the application, FAM177A1 has an inhibiting effect on MAPK, FAM177A1 can become a target for resisting cardiac hypertrophy, so as to prevent or treat occurrence and development of cardiac hypertrophy; and FAM177A1 can also be used as a product for diagnosing and treating cardiac hypertrophy caused by peripheral vascular resistance such as aortic arch constriction and hypertension.